Puracyp

We are the world leader in transcriptional analysis of ADMET genes. Assessing gene transcription as an endpoint for determining induction of drug metabolizing enzymes and transporters has become the “method of choice” in the FDA’s latest draft Guidance for Industry drug interaction studies. Increased gene transcription due to NCE exposure, can be determined by two distinct methods, nuclear receptor activation and changes in mRNA levels in primary cultures. Puracyp has become the “gene transcription company” by providing both of these services. Our newest products meet the regulatory challenges associated with induction guidelines.